Pulmonary Fibrosis is a long-term condition that requires ongoing management. Initial evaluation usually takes 2 to 5 days, while pulmonary rehabilitation programs generally continue for 6 to 12 weeks. Medical treatment and follow-up are individualized ac
Most patients receive treatment on an outpatient basis. Patients requiring bronchoscopy, cryobiopsy, or advanced respiratory care may require 2 to 5 days of hospitalization.
Routine medical treatment does not require anesthesia. Bronchoscopy and transbronchial cryobiopsy are generally performed under local anesthesia with sedation or general anesthesia, depending on the procedure.
2,500 to 12,000 USD*
Pulmonary Fibrosis is a serious form of Interstitial Lung Disease (ILD) in which the lung tissue becomes scarred, thickened, and stiff over time, making it increasingly difficult for the lungs to expand and transfer oxygen into the bloodstream. As the disease progresses, patients may experience worsening breathlessness, persistent dry cough, fatigue, and reduced physical activity. Although lung scarring cannot usually be reversed, early diagnosis and advanced treatment can slow disease progression, improve breathing, reduce symptoms, and significantly enhance quality of life.
India has become one of the world's leading destinations for advanced and affordable Pulmonary Fibrosis and ILD treatment. Patients from Africa, the Middle East, and many other countries choose India because of its internationally accredited hospitals, experienced pulmonologists, ILD specialists, advanced respiratory care units, and comprehensive pulmonary rehabilitation programs at considerably lower costs than many developed nations.
Recent advancements in ILD management have transformed patient care. Leading hospitals in India now offer High-Resolution CT (HRCT) Imaging, Advanced Pulmonary Function Testing (PFT), Cryobiopsy, Endobronchial Ultrasound (EBUS), Multidisciplinary ILD Board Evaluation, Antifibrotic Therapy, Precision Autoimmune Testing, AI-assisted HRCT Analysis, Long-Term Oxygen Therapy (LTOT), Pulmonary Rehabilitation Programs, Tele-Pulmonology Follow-up, and Lung Transplantation for selected patients. These innovations help improve diagnostic accuracy, delay disease progression, reduce hospitalizations, and improve long-term survival.
Whether you have Idiopathic Pulmonary Fibrosis (IPF), connective tissue disease-associated ILD, hypersensitivity pneumonitis, sarcoidosis, occupational lung disease, or other forms of interstitial lung disease, India offers comprehensive treatment with international standards of quality, safety, and personalized patient care.
Patients with Pulmonary Fibrosis or ILD may experience:
Patients experiencing progressive breathlessness should seek early evaluation by a pulmonologist.
Several factors increase the risk of Pulmonary Fibrosis and ILD, including:
Before treatment, patients undergo comprehensive respiratory evaluation to determine the type and severity of ILD.
Diagnostic tests may include:
International patients can submit their medical reports online to receive an expert opinion before travelling to India.
Treatment is personalized according to the type of ILD, severity of lung fibrosis, underlying cause, and overall health.
Antifibrotic Therapy
Patients with Idiopathic Pulmonary Fibrosis (IPF) and selected progressive fibrosing ILDs may receive antifibrotic medications that help slow the progression of lung scarring.
Immunosuppressive Therapy
Patients with autoimmune-related ILD may benefit from corticosteroids or immunosuppressive medications to reduce inflammation and prevent further lung damage.
Pulmonary Rehabilitation
Comprehensive rehabilitation programs including breathing exercises, supervised physical training, nutritional counseling, and patient education improve lung function and daily activities.
Long-Term Oxygen Therapy (LTOT)
Patients with low oxygen levels may require oxygen therapy to improve breathing, exercise capacity, and quality of life.
Non-Invasive Ventilation (NIV)
Advanced respiratory support may be recommended for selected patients with respiratory failure.
Lung Transplant
Patients with advanced Pulmonary Fibrosis who no longer respond to medical treatment may be evaluated for lung transplantation.
Medical Management
Antifibrotic medications, immunosuppressive therapy, oxygen therapy, vaccinations, and lifestyle modifications.
Pulmonary Rehabilitation
Structured rehabilitation improves exercise capacity, breathing efficiency, and overall health.
Interventional Pulmonology
Cryobiopsy, bronchoscopy, and advanced diagnostic procedures for accurate diagnosis.
Lung Transplantation
Recommended for carefully selected patients with end-stage pulmonary fibrosis.
Patients receive continuous monitoring and long-term respiratory care.
Post-treatment care includes:
Although Pulmonary Fibrosis is a chronic condition, modern treatment can significantly improve quality of life and slow disease progression. Early diagnosis, antifibrotic therapy, pulmonary rehabilitation, oxygen therapy, healthy nutrition, vaccination, and regular follow-up help patients remain active and independent for longer.
For patients with advanced disease, timely referral for lung transplantation provides an opportunity for improved survival and quality of life. Leading respiratory centers in India offer multidisciplinary care focused on long-term disease management and patient well-being.
Patients with Pulmonary Fibrosis or ILD may experience:
Patients experiencing progressive breathlessness should seek early evaluation by a pulmonologist.
Several factors increase the risk of Pulmonary Fibrosis and ILD, including:
Before treatment, patients undergo comprehensive respiratory evaluation to determine the type and severity of ILD.
Diagnostic tests may include:
International patients can submit their medical reports online to receive an expert opinion before travelling to India.
Treatment is personalized according to the type of ILD, severity of lung fibrosis, underlying cause, and overall health.
Antifibrotic Therapy
Patients with Idiopathic Pulmonary Fibrosis (IPF) and selected progressive fibrosing ILDs may receive antifibrotic medications that help slow the progression of lung scarring.
Immunosuppressive Therapy
Patients with autoimmune-related ILD may benefit from corticosteroids or immunosuppressive medications to reduce inflammation and prevent further lung damage.
Pulmonary Rehabilitation
Comprehensive rehabilitation programs including breathing exercises, supervised physical training, nutritional counseling, and patient education improve lung function and daily activities.
Long-Term Oxygen Therapy (LTOT)
Patients with low oxygen levels may require oxygen therapy to improve breathing, exercise capacity, and quality of life.
Non-Invasive Ventilation (NIV)
Advanced respiratory support may be recommended for selected patients with respiratory failure.
Lung Transplant
Patients with advanced Pulmonary Fibrosis who no longer respond to medical treatment may be evaluated for lung transplantation.
Medical Management
Antifibrotic medications, immunosuppressive therapy, oxygen therapy, vaccinations, and lifestyle modifications.
Pulmonary Rehabilitation
Structured rehabilitation improves exercise capacity, breathing efficiency, and overall health.
Interventional Pulmonology
Cryobiopsy, bronchoscopy, and advanced diagnostic procedures for accurate diagnosis.
Lung Transplantation
Recommended for carefully selected patients with end-stage pulmonary fibrosis.
Patients receive continuous monitoring and long-term respiratory care.
Post-treatment care includes:
Although Pulmonary Fibrosis is a chronic condition, modern treatment can significantly improve quality of life and slow disease progression. Early diagnosis, antifibrotic therapy, pulmonary rehabilitation, oxygen therapy, healthy nutrition, vaccination, and regular follow-up help patients remain active and independent for longer.
For patients with advanced disease, timely referral for lung transplantation provides an opportunity for improved survival and quality of life. Leading respiratory centers in India offer multidisciplinary care focused on long-term disease management and patient well-being.
Is Pulmonary Fibrosis treatment affordable in India?
Yes. Treatment in India is significantly more affordable than in many developed countries while maintaining international standards of respiratory care.
Can Pulmonary Fibrosis be cured?
Most forms of Pulmonary Fibrosis cannot be completely cured. However, early diagnosis and advanced treatments can slow disease progression, reduce symptoms, and improve quality of life.
What are the latest advancements in ILD treatment?
Recent advancements include antifibrotic therapy, AI-assisted HRCT analysis, transbronchial cryobiopsy, multidisciplinary ILD evaluation, precision autoimmune testing, pulmonary rehabilitation, tele-pulmonology, and lung transplantation for eligible patients.
Can international patients receive ILD treatment in India?
Yes. International patients receive comprehensive assistance including online consultations, medical visas, accommodation, airport transfers, interpreter services, pulmonary rehabilitation, and follow-up care.
When is lung transplantation recommended?
Lung transplantation may be considered for carefully selected patients with advanced pulmonary fibrosis whose disease continues to progress despite optimal medical treatment.
Does pulmonary rehabilitation improve breathing?
Yes. Pulmonary rehabilitation is an important part of ILD management and helps improve exercise capacity, reduce breathlessness, and enhance overall quality of life.
Rockland Qutab, South Delhi, B 33- 34,Qutub Institutional Area, Katwaria Sarai – New Delhi
Sector 51 Gurgaon, Haryana 122 017, INDIA
Sector – 44, Opposite HUDA City Centre, Gurgaon, Haryana – 122002, India
Sarita Vihar, Mathura Road, New Delhi – 110076 , INDIA